#BEGIN_DRUGCARD DB00638

# AHFS_Codes:
Not Available

# ATC_Codes:
V04CH01

# Absorption:
Poorly absorbed, passes through to urine unmetabolized

# Biotransformation:
Metabolized into carbon dioxide and methane by colonic bacteria

# Brand_Mixtures:
Not Available

# Brand_Names:
Inulin USP 27
Inulin from Jerusalem artichokes

# CAS_Registry_Number:
9005-80-5

# ChEBI_ID:
15443

# Chemical_Formula:
C228H382O191

# Chemical_IUPAC_Name:
(2R,3R,4S,5S,6R)-2-{[(2S,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-2-({[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A starch found in the tubers and roots of many plants. Since it is hydrolyzable to fructose, it is classified as a fructosan. It has been used in physiologic investigation for determination of the rate of glomerular function. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Diagnostic Agents
Hypoglycemic Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
10395609	Coussement PA: Inulin and oligofructose: safe intakes and legal status. J Nutr. 1999 Jul;129(7 Suppl):1412S-7S.
12514257	Coudray C, Demigne C, Rayssiguier Y: Effects of dietary fibers on magnesium absorption in animals and humans. J Nutr. 2003 Jan;133(1):1-4.
15877886	Roberfroid MB: Introducing inulin-type fructans. Br J Nutr. 2005 Apr;93 Suppl 1:S13-25.
16087995	Abrams SA, Griffin IJ, Hawthorne KM, Liang L, Gunn SK, Darlington G, Ellis KJ: A combination of prebiotic short- and long-chain inulin-type fructans enhances calcium absorption and bone mineralization in young adolescents. Am J Clin Nutr. 2005 Aug;82(2):471-6.

# Drug_Type:
Approved
Nutraceutical
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
280 mg/mL (at 80 °C), insoluble at room temperature

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Inulin

# HET_ID:
Not Available

# Half_Life:
2-4 hours

# InChI_Identifier:
InChI=1S/C228H382O191/c229-1-76-114(268)152(306)153(307)191(381-76)419-228(190(344)151(305)113(38-266)418-228)75-380-227(189(343)150(304)112(37-265)417-227)74-379-226(188(342)149(303)111(36-264)416-226)73-378-225(187(341)148(302)110(35-263)415-225)72-377-224(186(340)147(301)109(34-262)414-224)71-376-223(185(339)146(300)108(33-261)413-223)70-375-222(184(338)145(299)107(32-260)412-222)69-374-221(183(337)144(298)106(31-259)411-221)68-373-220(182(336)143(297)105(30-258)410-220)67-372-219(181(335)142(296)104(29-257)409-219)66-371-218(180(334)141(295)103(28-256)408-218)65-370-217(179(333)140(294)102(27-255)407-217)64-369-216(178(332)139(293)101(26-254)406-216)63-368-215(177(331)138(292)100(25-253)405-215)62-367-214(176(330)137(291)99(24-252)404-214)61-366-213(175(329)136(290)98(23-251)403-213)60-365-212(174(328)135(289)97(22-250)402-212)59-364-211(173(327)134(288)96(21-249)401-211)58-363-210(172(326)133(287)95(20-248)400-210)57-362-209(171(325)132(286)94(19-247)399-209)56-361-208(170(324)131(285)93(18-246)398-208)55-360-207(169(323)130(284)92(17-245)397-207)54-359-206(168(322)129(283)91(16-244)396-206)53-358-205(167(321)128(282)90(15-243)395-205)52-357-204(166(320)127(281)89(14-242)394-204)51-356-203(165(319)126(280)88(13-241)393-203)50-355-202(164(318)125(279)87(12-240)392-202)49-354-201(163(317)124(278)86(11-239)391-201)48-353-200(162(316)123(277)85(10-238)390-200)47-352-199(161(315)122(276)84(9-237)389-199)46-351-198(160(314)121(275)83(8-236)388-198)45-350-197(159(313)120(274)82(7-235)387-197)44-349-196(158(312)119(273)81(6-234)386-196)43-348-195(157(311)118(272)80(5-233)385-195)42-347-194(156(310)117(271)79(4-232)384-194)41-346-193(155(309)116(270)78(3-231)383-193)40-345-192(39-267)154(308)115(269)77(2-230)382-192/h76-191,229-344H,1-75H2/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152+,153-,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,181+,182+,183+,184+,185+,186+,187+,188+,189+,190+,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,221-,222-,223-,224-,225-,226-,227-,228+/m1/s1

# InChI_Key:
InChIKey=JYJIGFIDKWBXDU-MNNPPOADSA-N

# Indication:
Historically used in an important medical test of renal function, specifically a measure of glomerular filtration rate. Sometimes used to help relieve symptoms of diabetes mellitus - a condition characterised by hyperglycemia and/or hyperinsulinemia.

# KEGG_Compound_ID:
C03323

# KEGG_Drug_ID:
D00171

# LIMS_Drug_ID:
638

# Mechanism_Of_Action:
As a diagnostic agent, inulin is readily soluble and essentially indigestible. It readily passes through the blood and into the urine. It is neither secreted nor resorbed by the kidney making it an excellent indicator for renal clearance rates. The inulin clearance test has largely been succeeded by the creatinine clearance test as a measure of glomerular filtration rate. As a hypoglycemic agent, inulin is not digestible by human enzymes ptyalin and amylase, which are designed to digest starch. As a result, inulin passes through much of the digestive system intact. It is only in the colon that bacteria metabolise inulin, with the release of significant quantities of carbon dioxide and/or methane. Because inulin is not broken down into simple sugars (monosaccharides) by normal digestion, it does not elevate blood sugar levels, hence, helping diabetics regulate blood sugar levels.

# Melting_Point:
178 °C

# Molecular_Weight_Avg:
6179.3581

# Molecular_Weight_Mono:
6176.017855026

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/inu_0299.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA450043

# Pharmacology:
The inulin test is a procedure by which the filtering capacity of the glomeruli (the main filtering structures of the kidney) is determined by measuring the rate at which inulin, the test substance, is cleared from blood plasma. Inulin is one of the more suitable and accurate substance to measure because it is a small, inert polysaccharide molecule that readily passes through the glomeruli. The inulin clearance test is performed by injecting inulin, waiting for it to be distributed, and then measuring plasma and urine inulin concentrations by various assays. As nutraceutical agents inulins may have antitumor, antimicrobial, hypolipidemic and hypoglycemic actions. They may also help to improve mineral absorption and balance and may have antiosteoporotic activity.

# Predicted_LogP_Hydrophobicity:
0

# Predicted_LogS:
0

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB00638

# Protein_Binding:
None

# PubChem_Compound_ID:
24763

# PubChem_Substance_ID:
46508287

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD01034

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(OC[C@@]%12(OC[C@@]%13(OC[C@@]%14(OC[C@@]%15(OC[C@@]%16(OC[C@@]%17(OC[C@@]%18(OC[C@@]%19(OC[C@@]%20(OC[C@@]%21(OC[C@@]%22(OC[C@@]%23(OC[C@@]%24(OC[C@@]%25(OC[C@@]%26(OC[C@@]%27(OC[C@@]%28(OC[C@@]%29(OC[C@@]%30(OC[C@@]%31(OC[C@@]%32(OC[C@@]%33(OC[C@@]%34(OC[C@@]%35(OC[C@@]%36(OC[C@@]%37(O[C@H]%38O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%38O)O[C@H](CO)[C@@H](O)[C@@H]%37O)O[C@H](CO)[C@@H](O)[C@@H]%36O)O[C@H](CO)[C@@H](O)[C@@H]%35O)O[C@H](CO)[C@@H](O)[C@@H]%34O)O[C@H](CO)[C@@H](O)[C@@H]%33O)O[C@H](CO)[C@@H](O)[C@@H]%32O)O[C@H](CO)[C@@H](O)[C@@H]%31O)O[C@H](CO)[C@@H](O)[C@@H]%30O)O[C@H](CO)[C@@H](O)[C@@H]%29O)O[C@H](CO)[C@@H](O)[C@@H]%28O)O[C@H](CO)[C@@H](O)[C@@H]%27O)O[C@H](CO)[C@@H](O)[C@@H]%26O)O[C@H](CO)[C@@H](O)[C@@H]%25O)O[C@H](CO)[C@@H](O)[C@@H]%24O)O[C@H](CO)[C@@H](O)[C@@H]%23O)O[C@H](CO)[C@@H](O)[C@@H]%22O)O[C@H](CO)[C@@H](O)[C@@H]%21O)O[C@H](CO)[C@@H](O)[C@@H]%20O)O[C@H](CO)[C@@H](O)[C@@H]%19O)O[C@H](CO)[C@@H](O)[C@@H]%18O)O[C@H](CO)[C@@H](O)[C@@H]%17O)O[C@H](CO)[C@@H](O)[C@@H]%16O)O[C@H](CO)[C@@H](O)[C@@H]%15O)O[C@H](CO)[C@@H](O)[C@@H]%14O)O[C@H](CO)[C@@H](O)[C@@H]%13O)O[C@H](CO)[C@@H](O)[C@@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:31 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Inulin

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2611778	Kawamura M, Uchiyama T, Kuramoto T, Tamura Y, Mizutani K: Formation of a cycloinulo-oligosaccharide from inulin by an extracellular enzyme of Bacillus circulans OKUMZ 31B. Carbohydr Res. 1989 Oct 23;192:83-90.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
AF222787

# Drug_Target_1_GenBank_ID_Protein:
12056574

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
cft

# Drug_Target_1_Gene_Sequence:
>4002 bp
ATGAGGAAAGTCAAAAGAGGGAAATGTTGGATATCGGGAATGGTTATATGGGCTATGGTG
CTCCAGCTTGTTGTTCCGGGAATTTCTGTCGCGTCCGAAAATAGAACTGTTGCTGGAGAA
ACGCTCATTCCTAAGAATGATGTGAAATCATCGGTTACGGATGCGATTTATCAAATCAAG
AATATTCCTCAGAATGACATGGGATTGTCAGTTACAGATTCAGTCTATCAAATCCGGAAT
CCTGGATTTGAAACAGGAGATTTGACGGGATGGACCGTTATCAAAGGCGATGCGTTCGGT
CCGAATAGCGTAACCGACGAAACGACTTGGTGGGCAGAAAAAATACCGTATAACCAGGAA
GGAGCTTATCATTTAAACGGCTGGAAGTATGACGAATCTGCGACAGGTGTACTTCGTTCC
AGCACTTTCGAGCTGGGCGGAAGCGGCGGGATCAGCTTCAAGCTTGGCGGTGCAAAGAAC
CCAGACAAGGTATTTATAAATATTGTGGAAGTCGATACGGGACAAGTTATTGCCCGATAC
GGAAATAGCGCATTCGCCGACGTTGGCTTCCCGGATCCTGCGCAGGGCATGCGGCTTGCC
AATATGGTGCAATACAAGGCGGATCTTTCCACACAATTGGGCAAGAAACTGTATGTGGAG
GTCGTCGATAATGCAACCTCGGATTGGGGAGTCATTTTTGCGGACGCATTCTCCATGTAC
CATGAGTCGGAGCCAGCTGAAGGAATTGTTGCGACGGATATCAAGCCGGATTTCAAGCGC
TATGAAATCGATAATCCAAGCTTTGAAACCGGAAATCTCGATGGCTGGACGGTTGAGGAA
GATGCTTTTGAAGTGACTGATGAAGCTCATGCGAGCAAAGAAGGGAACTTTTATGCCAAA
TCCTCCCTGCAAGGAAAGGGCTCCATCACTTCTAATACTTTCACGCTTCAGGGAACAGGA
ACAATTAATTTTACTGTTTTGGATATCCTCAAACCGGAAAATGCATATGTTGCACTTTTC
GATGCGAACAGCAACACATTGCTTATGAAAACCGGGAATGTCAGCGCGAACGAGAAAATC
TCATGGAAAGTGCAAGAACACTACAACAAGAAGCTCTATGTAAAGGTTGTCGATCATTCC
AATGAAGCCAGCATTGCCGTTGATAGTTTCCAAGCAAGTGATAGGGGGACTATTTTCTAC
TTAAACCTTGATGAAGGCGCAGGAAAGAAAGCGTTGGAGAAAGTACACAATCTTAGGCAC
GATGTGAACTATGTATTTAACAACGCCAGGTATATGGCATCGAAGGATCCGAGATGGACT
CCGCGTGGAATAAAAGGCGGCGCCTTATTGTTCGATGGATCCTCGAATTATATTGAGGTC
AATGCAAACGTTACTGTGCCTGTAAGCGACGCGTTAACCATCGAAGCTTGGGTTGCACCG
CGTAGCTATGAGTGGGGAGACGGAAACAAGCTGTCTGCGATCGTAAACCAATCCGACCAG
GATAAAGCGGAAGGCTTTTCTCTTGGTATGTATCGGCACGGTACATGGTCGATGCAAGTA
GGCATCGGCGGTCAGTGGATTCAGGTATGGGTAAAGGATCACCCGTTGGAAAAATACAAG
TGGAATTATGTGGCCGCTACTTTCAGTAAAGAAGATGGAAAAATTAAGTTATATCTAAAC
GGTGAGGAAGTGGCTTCCCAAGCAACCCCCGTCAACGTTCCGATCACACCATCTACCGAA
AGCCTGATCATCGGGAAAAATAATAAACCTGTAGAGTTAGCAGGGGTGTTCTCCTTCAAT
ATGTTCAGCGGACTCCTAGATGAAGTGAAGCTGCATAATAAAGCCCTTACGAACCAGGAG
ATACTTGCTGGATATGAGAGCGTGAAGGCGCTTCATGGAGGTTCAATTCCGAAAATTCCG
AATGCGGACATTGATGAGGATCCAAGTGTGTTTGACGGAGATCAGCACCGACCCCAGTAC
CACGCGATGCCTCCGCAAAACTGGATGAATGAAGCACATGCACCGATTTACTATAACGGC
AAATACCATTTATTTTATCAACATAACCCGCAAGGTCCATTCTGGCATCAAATCCACTGG
GGGCATTGGGTGAGTGACGATATGGTGAACTGGGAAAATGTAAGACCTGCTCTTGCGCCC
GAAGCGGGCACCCTAGATCCGGACGGCACGTGGTCAGGCAGTGCAGCGTATGATCGAAAC
GGCAATCCTGTTCTGTTCTATACCGCTGGCAACGACTCCTTGTCGCCGAACCAAAGAACA
GGGTTGGCAACTCCGGCGGATTTGTCCGATCCCTATTTGGAAAAATGGGAGAAATATCCT
AAACCGGTAACGGAGCAGAACGGAAAAGGCATCCACAACGAGTTCCGCGATCCGTTTGTA
TGGTACGACAAAGAGGTGGACAAGTGGTATCAGTTAGTGACATCTGGTCTTCCAGACTTC
AGCAGCGGCACAGCTTTGGTGTATGTATCCGATGATATGTACAATTGGAAATATAAGGGA
CCGTTATACGTTAGTGACAGAATCCGTTATCCGGAGTTGGGTACGGTATGGGAGCTACCA
GTGTTATTGCCGTTAGGCACGGATAGTACGGGCAAGCAAAAATATATTTTCATGATTAAT
CCCCATGAAAAGCCGGAGCATGTTCCTCCAGCGAACGATGTGCAAAGAGATGTTGAGGTC
TTTTACTGGATCGGGACCTGGGACCGGGATAACTTTAAATTTATTCCTGATCAGGAGGCA
CCCTCCAAAATGGATGTAGGTGACGGCTATTTAACCGCAGAGAGCGGTCTGGTCACACCC
GACGGAAGAACGGTCGTATTCTCTATGGTGCAAAATGTAAGAACACCGCAAGCCGAATAT
CAATCTGGATGGGCTCATAATTTATCTTTGCCGGTTTCCCTAAGCCTCGATAAGTATGAT
AAATTGCATATCGAACCGATTAAAGAACTGCAGAGCCTTCGAGGGGAAAAATGGGTTGAT
TTTTCGGACAAAAATTTGGAGAGTGCCAATCAATTGATTAAGAATGTCAAAGGCGACATG
CTAGAGATTGTGATGGAGATTGATCCGCGTGAAGCCCAGAAATTTGGTCTCAAGGTGCGA
CGCTCGGAAAAAGGCCAAGAAGAGACGCTCATTTACTACGACAAGAAGAACGGGACGTTT
AATGTGGATCGAACCAAGAGCAGCATTGATCCGGATGTGCGTGTAGACGGCATTCAAGGA
GGATATGTAGATCTTGAAGGAGAGAACTTGAAACTCCATATCTTTCTTGATCGCTCGGTC
ATTGAAGCCTTTGCAAATTACAAGAAGAAGCTGACAACTCGTGTCTATGTAGGCAGATAC
GACTCCTTAGGCTTACAGATCTGGGCCGATGGCGATATCAATATCAAATCCATGCAAGTA
TGGGATATGAATGCCTTAACGGGTAAACCGGCTGCTCCGGTCTATGTACCCGATAAGTGG
GATAATTCTGTGTATAAGGATATTACAGAGCTGCCTAACCATGATTTTGCTACGGGCGAC
TTAACAGGATGGATGACGGAAGGAGACGCCTTCCAGAATGTCCATGTGACCAATACCCAG
TTCTTCTGGGACAACATTTTCTTCAACCCGTCGCATAAAATTCCGGGCAGCTACCATTTG
TGGGGCTTCAACGAGCAAGCCGGCGGCGACAGCTTAACCGGAGCGCTAAGATCTCAAAAT
TTCGTCCTTGGTGGGAACGGTAAGATCAACTTCCTTATCAGCGGAGGCCGGGATATAGAT
CGTCTGTATGTTGCGCTGGTTCGGGCGTCGGACGACAAAGAGTTATTTAAAGAGACAGCG
ACCAATTATGAGGAATATCAACGTAAGATTTGGGATGCGACGGATTATATCGGGGAGGAG
CTTTATATAAAGGTGGTTGACCACTCCAAAGGCGGGTTTGGACATATTAACGTCGATGAT
TTTAATGTACCTGTTCAGGTAAAGAAGAAAACTAACAACTGA

# Drug_Target_1_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_1_General_References:
11157277	Kim HY, Choi YJ: Molecular characterization of cycloinulooligosaccharide fructanotransferase from Bacillus macerans. Appl Environ Microbiol. 2001 Feb;67(2):995-1000.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4107

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
149564

# Drug_Target_1_Name:
Cycloinulo-oligosaccharide fructanotransferase

# Drug_Target_1_Number_of_Residues:
1333

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00251	Glyco_hydro_32N
PF08244	Glyco_hydro_32C

# Drug_Target_1_Protein_Sequence:
>Cycloinulo-oligosaccharide fructanotransferase
MRKVKRGKCWISGMVIWAMVLQLVVPGISVASENRTVAGETLIPKNDVKSSVTDAIYQIK
NIPQNDMGLSVTDSVYQIRNPGFETGDLTGWTVIKGDAFGPNSVTDETTWWAEKIPYNQE
GAYHLNGWKYDESATGVLRSSTFELGGSGGISFKLGGAKNPDKVFINIVEVDTGQVIARY
GNSAFADVGFPDPAQGMRLANMVQYKADLSTQLGKKLYVEVVDNATSDWGVIFADAFSMY
HESEPAEGIVATDIKPDFKRYEIDNPSFETGNLDGWTVEEDAFEVTDEAHASKEGNFYAK
SSLQGKGSITSNTFTLQGTGTINFTVLDILKPENAYVALFDANSNTLLMKTGNVSANEKI
SWKVQEHYNKKLYVKVVDHSNEASIAVDSFQASDRGTIFYLNLDEGAGKKALEKVHNLRH
DVNYVFNNARYMASKDPRWTPRGIKGGALLFDGSSNYIEVNANVTVPVSDALTIEAWVAP
RSYEWGDGNKLSAIVNQSDQDKAEGFSLGMYRHGTWSMQVGIGGQWIQVWVKDHPLEKYK
WNYVAATFSKEDGKIKLYLNGEEVASQATPVNVPITPSTESLIIGKNNKPVELAGVFSFN
MFSGLLDEVKLHNKALTNQEILAGYESVKALHGGSIPKIPNADIDEDPSVFDGDQHRPQY
HAMPPQNWMNEAHAPIYYNGKYHLFYQHNPQGPFWHQIHWGHWVSDDMVNWENVRPALAP
EAGTLDPDGTWSGSAAYDRNGNPVLFYTAGNDSLSPNQRTGLATPADLSDPYLEKWEKYP
KPVTEQNGKGIHNEFRDPFVWYDKEVDKWYQLVTSGLPDFSSGTALVYVSDDMYNWKYKG
PLYVSDRIRYPELGTVWELPVLLPLGTDSTGKQKYIFMINPHEKPEHVPPANDVQRDVEV
FYWIGTWDRDNFKFIPDQEAPSKMDVGDGYLTAESGLVTPDGRTVVFSMVQNVRTPQAEY
QSGWAHNLSLPVSLSLDKYDKLHIEPIKELQSLRGEKWVDFSDKNLESANQLIKNVKGDM
LEIVMEIDPREAQKFGLKVRRSEKGQEETLIYYDKKNGTFNVDRTKSSIDPDVRVDGIQG
GYVDLEGENLKLHIFLDRSVIEAFANYKKKLTTRVYVGRYDSLGLQIWADGDINIKSMQV
WDMNALTGKPAAPVYVPDKWDNSVYKDITELPNHDFATGDLTGWMTEGDAFQNVHVTNTQ
FFWDNIFFNPSHKIPGSYHLWGFNEQAGGDSLTGALRSQNFVLGGNGKINFLISGGRDID
RLYVALVRASDDKELFKETATNYEEYQRKIWDATDYIGEELYIKVVDHSKGGFGHINVDD
FNVPVQVKKKTNN

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q9F0I5

# Drug_Target_1_SwissProt_Name:
Q9F0I5_PAEMA

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
4.95

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB00638
